We are IntechOpen,

the world’s leading publisher of

Open Access books
Built by scientists, for scientists

4,900
Open access books available
123,000
International authors and editors
140M Downloads

Our authors are among the

154
Countries delivered to
TOP 1%
most cited scientists
12.2%
Contributors from top 500 universities

Selection of our books indexed in the Book Citation Index

in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?

Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Chapter

Dengue Fever: An Overview

Ramalingam Kothai and Balasubramanian Arul

Abstract

Dengue fever is a disease caused by a family of viruses transmitted by mosqui-

toes. Dengue virus (DENV), a member of the Flaviviridae family, causes the most
widespread mosquito-borne viral infection in humans around the world today.
Dengue can affect anyone but tends to be more severe in people with compromised
immune systems. Dengue hemorrhagic fever is a more severe form of a viral illness.
Symptoms include headache, fever, rash, and evidence of bleeding (hemorrhage) in
the body. This form of dengue fever can be life-threatening and can progress to the
most severe form of the illness, dengue shock syndrome. This chapter reviews the
etiology, epidemiology, diagnosis, pathophysiology, transmissions, manifestations,
diagnosis, treatment, and prevention of dengue.

Keywords: dengue, etiology, epidemiology, pathophysiology

1. Introduction

Dengue fever is a mosquito-borne viral infection which has a sudden onset that
follows symptoms such as headache, nausea, weakness, intense muscle and joint
pain, swelling of lymph nodes (lymphadenopathy), and rashes on the skin. Many
symptoms of dengue fever include gingivitis, sharp pain in the eyes, and swollen
palms and soles.
Dengue can affect any person but appears to be more serious in immunocom-
promised people. Because it is caused by one of the five dengue virus serotypes, it is
possible to have dengue fever multiple times. Nonetheless, a dengue attack provides
lifelong immunity to the specific viral serotype to which the patient has been
exposed. This disease may also be called “breakbone fever” or “dandy fever.”
This dengue fever may become more serious and then named as dengue hemor-
rhagic fever and dengue shock syndrome. Dengue hemorrhagic fever is a more severe
form in which hemorrhages occurs in the body. It is a life-threatening condition, and
it may progress to the most critical form called dengue shock syndrome [1].

2. Etiology

Dengue virus (DENV) is a single-stranded, positive-sense RNA virus in the

Flaviviridae family and the Flavivirus genus. When viewed under the transmission
electron micrograph, the virions appear as a bunch of black spots. Yellow fever
virus, West Nile virus, St. Louis encephalitis virus, Japanese encephalitis virus, tick-
borne encephalitis virus, Kyasanur Forest disease virus, and Omsk hemorrhagic
fever virus belong to this family, and majority of them is transmitted by arthropods
(mosquitoes or ticks) [2].

1
Dengue Fever

Approximately 11,000 nucleotide bases were present in the dengue genome, which
codes for a single polyprotein. It is made up of three structural protein molecules (C,
prM, and E) that constitute the virus particle and seven nonstructural proteins (NS1,
NS2a, NS2b, NS3, NS4a, NS4b, and NS5) which are required for viral replication [3, 4].
The five strains of the virus (DENV-1, DENV-2, DENV-3, DENV-4, and DENV-5) are
referred to as serotypes because they vary in serum reactivity (antigenicity) [5].
The main cause of dengue fever is an infected mosquito bite [6], and besides it,
it may be accidentally acquired after vertical transmission, especially in near-term
pregnant women through the placenta [7], infected blood products [8], through
organ transplantation [9], and even after needle stick injury [10].

3. Epidemiology

Awareness about the terrestrial spread and impact of dengue is relevant for
assessing its relation to worldwide morbidity and mortality and knowing how to
utilize the available resources for controlling the dengue globally.
Only nine countries had suffered major epidemics of dengue, before 1970.
Currently it is common in most of the regions of the WHO. The Americas, South
East Asia, and Western Pacific areas are the most severely affected, with Asia
responsible for around 70% of the global disease burden. Throughout the recent
decades, the prevalence of dengue has significantly elevated around the globe. The
vast majority of cases are asymptomatic or mild and self-managed, and therefore
the actual number of dengue cases is underreported. Many cases are also misdiag-
nosed as other febrile disorders [11].
One report indicates 390 million dengue virus infections per year, of which 96
million occur clinically (with any disease severity). The report on dengue prevalence
reports that 3.9 billion people are at risk of infection with dengue viruses. Despite the
risk of infection in 128 countries, 70% of the real burden is from Asia [12].
The number of dengue cases recorded to WHO has risen ~6 fold, from <0.5
million in 2010 to more than 3.34 million in 2016. The year 2016 was marked by
massive dengue outbreaks worldwide. A major reduction in the number of dengue
cases in the Americas was reported in 2017, from 2,177,171 cases in 2016 to 584,263
cases in 2017. It reflects a drop of 73%. Following a drop in the number of cases in
2017–2018, a sharp increase in cases is reported in 2019. Cases have increased in
Australia, Cambodia, China, Lao PDR, Malaysia, the Philippines, Singapore, and
Vietnam. An estimated 500,000 people with severe dengue require hospitalization
every year, and an estimated 2.5% of cases are fatal each year. Nevertheless, several
countries have lowered the case fatality rate to less than 1%, and internationally,
there has been a decline in case of fatality between 2010 and 2016, with a significant
improvement in case management through country-level capacity building. The
only continent that has not witnessed dengue transmission is Antarctica.
The global burden of dengue is formidable and is a growing challenge for public
health officials and policymakers. Success in addressing this growing global threat
depends, in part, on strengthening the evidence base on which planning control
decisions and their impact are assessed. It is hoped that this assessment of the distri-
bution and burden of contemporary dengue risk will help to advance this objective.

4. Pathophysiology

The pathophysiology of DENV and the immune response of the host are
not fully understood. Primary manifestations of disease include capillary leak

2
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

syndrome (plasma leakage due to DHF-specific endothelial cell dysfunction),

thrombocytopenia (seen in all types of DENV infection, but extreme in DHF),
hemorrhagic tendencies, and leukopenia. It is known that the major viral enve-
lope (E) of glycoprotein in the virus helps to bind the host cells, followed by viral
replication [13] . Data suggest that monocytes are the primary target [14]. Infected
monocytes induce the production of interferon-a (IFN-a) and IFN-b [15]. Envelope
(E), precursor membrane protein (pre-M), and nonstructural protein 1 (NS1)
are the major DENV proteins targeted by antibodies as part of the host immune
response. Studies have shown that DENV-specific CD4+ and CD8+ T lymphocytes
attack infected cells and release IFN-g, tumor necrosis factor-a (TNF-a), and
lymphotoxin. Primary infection induces a lifetime immunity of the individual to
that particular serotype, but not to secondary infection by another serotype.

5. Transmission

Dengue virus is the most common mosquito-borne infection in humans all over the
world. It belongs to the family Flaviviridae, which contains more than 70 viruses [16],
in which DENV is transmitted by the Aedes aegypti and Aedes albopictus mosquitoes
[17].
Dengue virus is spread primarily by Aedes mosquitoes, in particular Aedes aegypti.
These mosquitoes usually live between 35°N and 35°S below an altitude of 1000 m
(3300 feet) [5]. They usually bite especially in the early morning and in the evening.
Certain Aedes disease-borne species include Aedes albopictus, Aedes scutellaris, and
Aedes polynesiensis. Human beings are the primary hosts of this virus, arousing even
nonhuman primates. An infection may be obtained through a single bite. A female
mosquito that consumes an infected person’s blood (within a febrile, viremic span of

3
Dengue Fever

2 to 12 days) becomes infected with the virus in its intestine. The virus then spread
into other tissues, including the salivary glands of the mosquito, approximately after
a period of 8–10 days and is subsequently released into its saliva. When it bites the
other person, the virus is transmitted through its saliva to that person. The virus does
not cause any harm to the mosquito [18]. Aedes aegypti is a main concern as it prefers
to lay its eggs in containers of freshwater and stay close to humans. Infected blood
products and organ donation can also cause dengue [8, 9, 19]. Even in countries
like Singapore, the incidence is approximately 1.6 to 6 in 10,000 transfusions [20].
The vertical transmission (from mother to child) during pregnancy or at birth is
also documented [8]. Other person-to-person forms of transmission have also been
reported, but are very rare [21]. Dengue’s genetic variants are regionally specific,
indicating that the creation of new territories is relatively rare, despite the fact that
dengue has appeared in new regions in recent decades [22].

5.1 The virus

DENV is a small single-stranded RNA virus consisting of five different serotypes

(DENV-1 to DENV-5). The virus particle is spherical in shape with a diameter of
50 nm. The genome is divided into three structural proteins (capsid C prM, mem-
brane precursor M protein, and envelope E) and seven nonstructural proteins (NS)
by the host and viral proteases.
Within each serotype, distinct genotypes or lineages (viruses closely related in
nucleotide sequence) have been identified, demonstrating the substantial genetic
variability in dengue serotypes. However, purifying selection continues to be a
dominant theme in the evolution of dengue viruses, so only viruses that are “fit”
for both humans and vectors are retained. Between these, severe secondary dengue
infections are often associated with “European” genotypes DENV-2 and DENV-3
[23–25]. The human hosts have established intra-host viral diversity (quasi-species).

5.2 The vectors

Different dengue virus serotypes are transmitted to humans through the bites of
infected Aedes mosquitoes, mainly Aedes aegypti. This mosquito is a tropical and sub-
tropical species widely distributed around the world, mostly between 35°N and 35°S
latitudes. Such geographical limits correspond roughly to the 10°C winter isotherm.
Aedes aegypti was located as far north as 45°N, but in warmer months, these invasions
took place, and the mosquitoes did not survive the winter months. Aedes aegypti is
also relatively uncommon over 1000 m, due to lower temperatures. The embryonic
stages are found in water-filled settings, mostly in artificial containers that are closely
linked to human dwellings, and often inside. Research suggests that mostly female
Aedes aegypti may spend their lives in or around the homes where the adults emerge.
It means people are spreading the virus quickly within and between populations,
rather than mosquitoes. Aedes albopictus, Aedes polynesiensis, and several species of
Aedes scutellaris were also attributed to outbreaks of the dengue [26]. Each of these
species has a specific ecological, behavioral, and geographical distribution. Aedes
albopictus has spread from Asia to Africa, Americas, and Europe in recent decades,
aided particular by international trade in used tires, where eggs are deposited as they
contain rainwater. Eggs can remain viable for many months, in the absence of water.

5.3 The host

After an incubation period of 4–10 days, infection with any of the four
virus serotypes can cause a wide range of illnesses, although most infections are

4
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

asymptomatic or subclinical. Primary infection is thought to cause long-term

defensive immunity to serotype infections [27]. Around 2–3 months of primary
infection, but without long-term cross-protective immunity, individuals suffering
from infection are protected from clinical illness with a specific serotype.
Personal risk factors influence the severity of the disease and also include
secondary infections (bronchial asthma, sickle cell anemia, and diabetes mellitus),
age, race, and potentially chronic diseases. In particular, young children may be less
able to compensate for capillary leakage than adults and are thus at a higher risk of
dengue shock [5].
Seroepidemiological reports conducted in Cuba and Thailand strongly support
the position of secondary heterotypic infection as a risk factor for severe dengue,
although there is little evidence of serious primary infection cases [28–31]. Also,
the time interval between infections and the specific viral infection sequence may
be significant. For example, a higher fatality rate was observed in Cuba when DEN2
infection followed DEN-1 infection at an interval of 20 years compared to 4 years.
Severe dengue is also commonly seen in infants born to dengue-infected mothers.
Antibody-dependent enhancement (ADE) of the infection has been hypothesized
[32] as a mechanism to explain severe dengue in the course of secondary infection
and in infants with primary infections. In this model, non-neutralizing, cross-
reactive antibodies produced during primary infection or acquired passively at birth
bind to epitopes on the surface of the heterologous infective virus and promote the
entry of the virus into Fc-bearing cells. The increased number of infected cells is
expected to result in increased viral load and robust host immune response activa-
tion including inflammatory cytokines and mediators, some of which may contrib-
ute to capillary leakage. Cross-reactive memory T cells are also rapidly triggered
during secondary infection, proliferate, release cytokines, and die of apoptosis in
a manner that usually correlates with overall disease severity. Host genetic deter-
minants may have an effect on the clinical outcome of infection [33], although
most studies have not been able to address this problem adequately. Studies in the
American region indicate that the levels of extreme dengue in individuals of African
descent are lower than in other ethnic groups [34].
Recent data suggest that endothelial cell activation could mediate plasma leakage
[35, 36]. Plasma leakage is believed to be associated with functional effects on
endothelial cells, rather than harmful ones. Endothelial cell dysfunction may also
be associated with the activation of infected monocytes and T cells, the comple-
ment system, and the production of mediators, monokines, cytokines, and soluble
receptors.
Thrombocytopenia may be associated with alterations in megacaryocyto-
poiesis due to human hematopoietic cell infection and impaired progenitor
cell growth, resulting in platelet dysfunction (activation and aggregation of
platelets), increased destruction, or consumption (peripheral sequestration and
consumption). Hemorrhage may result from thrombocytopenia and related plate-
let dysfunction or intravascular coagulation. In short, a transient and reversible
imbalance of inflammatory mediators, cytokine, and chemokine occurs during
severe dengue times, probably due to high early viral loads, leading to vascular
endothelial cell dysfunction, hemocoagulation disorders, and then plasma
leakage, shock, and bleeding.

6. Manifestations

One of three clinical forms can be used in humans, such as dengue fever (DF),
dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS).

5
Dengue Fever

Approximately one-half of the DENV infections are asymptomatic, and some

are undifferentiated (in which the patient develops fever and mild symptoms, but
the source of the infection is not diagnosed as DENV). The three clinical forms
of the disease vary in the severity of their symptoms, with the influenza-like DF
being the least severe and the DSS being the most severe. In most cases, mild febrile
DF is not fatal; however, infections that develop into DHF or DSS may be life-
threatening and cause death in many cases. Patients with DHF and DSS were found
to have virus titers 100- to 1000-fold higher than those with DF from the initial
stage of infection [37]. Overall, DENV infection has been found to be more severe
in children than adults [38].
Based on the outcome of several studies, the WHO has developed a new dengue
classification. It differentiates dengue cases into cases with or without warning
signs and serious cases of dengue.
Usually, signs begin to appear after an incubation period of 3–10 days [39]. The
severity of clinical presentations ranges from mild symptoms to extreme life-threat-
ening symptoms for dengue hemorrhagic fever and dengue shock syndrome [40].
Predicting the progression of mild signs to severe DHF/DSS remains a challenge due
to unspecific clinical presentation and incomplete understanding of disease patho-
physiology and its underlying molecular mechanisms.
The early signs of the disease are nonspecific. According to WHO, DF is char-
acterized by febrile episodes (≥40°C for 2–7 days) often associated with rash,
nausea, vomiting, and headache. Even though the disease affects all ages of people
from infant to adulthood [41], epidemiological data showed that children tend to
control this disease better than adults [42]. The severity of the above symptoms
and the emergence of other symptoms, such as abdominal pain, mucosal bleeding,
and lethargy and restlessness, can be seen after 3–7 days. Laboratory examination
of mild dengue fever cases usually reveals elevated leukocyte counts and a small
increase in hepatic aminotransferase activity. The emergence of these symptoms is a
warning sign of disease progression to severe form (DHF/DSS) if therapeutic action
is not undertaken. At this level, clinical intervention and continuous surveillance
are necessary to prevent vascular leakage, especially in the endemic region.
Extreme dengue infection can be due to any of the four recognized DENV 1–4
serotypes. The likelihood of developing DHF/DSS is high in patients who have had
dengue infection with heterogeneous serotype [43] in the past, with approximately
5–10% of patients developing extreme DHF/DSS that can be fatal unless treated
promptly [44].
This type evolves at a late stage of DF, where patients will experience a defer-
vescent process characterized by a sudden drop in body temperature. This phase
is also characterized by severe bleeding, especially from the gastrointestinal tract
(black, tarry stool) and thrombocytopenia (<50,000/mm3), which may affect up
to 50% of DHF cases [45]. Ironically, there was a negative correlation between the
frequency of DHF and the number of platelets in the blood. The exact mechanism
of this association is yet to be identified. Decreased platelet counts and loss of func-
tion contribute to vascular fragility, increasing the risk of hemorrhage and plasma
leakage59. It has been proposed that DENV replicates rapidly in platelets during the
acute phase of infection, as this is very important to the survival and dissemination
of the virus [46]. The existence of other signs such as retro-orbital pain, macu-
lopapular rash, petechiae, or nose or gum bleeding may help to make a definitive
diagnosis of DF [47]. Subsistence in systolic pressure and hypotension can result in
profound shock, known as dengue shock syndrome. Long-term DSS duration can
predispose to additional complications such as severe bleeding, diffuse intravascu-
lar coagulopathy (DIC), respiratory failure, multiorgan failure, and infrequently
encephalopathy leading to death [48, 49]. It was estimated that DHF-related case

6
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

fatality could exceed 15% of all cases, but proper medical treatment and symptom-
atic management could minimize the mortality rate to less than 1%.
Signs and symptoms depending on the stage of the disease reflect the dengue
fever. People with dengue virus normally become asymptomatic (80%) or have
mild symptoms such as uncomplicated fever [50, 51]. 5 % of the people have more
severe illness and, in a small proportion of cases (<1%), are life-threatening and
cause death despite care. The incubation period (time between exposure and onset
of symptoms) ranges from 3 to 14 days, but most of the time is 4 to 7 days. Children
are more likely to have atypical symptoms, often with common cold or gastroenteri-
tis (vomiting and diarrhea)-like symptoms [52].
The characteristic symptoms of dengue are sudden fever, headache (typically
behind the eyes), muscle and joint pain, and rash. The course of infection is divided
into three phases: febrile, serious, and recovery. The febrile phase includes high fever,
possibly over 40°C (104°F) and is associated with severe pain and headache; this
period usually lasts 2–7 days. Vomiting and rash will be there along with flushed skin.
In some cases, the illness is progressing to a serious stage as the fever clears. This pro-
cess is characterized by major, diffuse plasma leakage usually lasting 1–2 days. Organ
dysfunction and severe bleeding, usually from the gastrointestinal tract, may also
occur [53]. Shock (dengue shock syndrome) and hemorrhage (dengue hemorrhagic
fever) occur in less than 5% of all dengue cases. This serious phase is more common
among children and young adults. The recovery phase is followed by the resorption of
the leaked fluid into the bloodstream over a duration of 2–3 days. The change is often
startling and can be followed by serious pruritus and bradycardia. The rash can occur,
with either a maculopapular or a vasculitic appearance accompanied by desquama-
tion. A fluid-overloaded condition can occur during this stage, in rare cases.
Dengue also affects a variety of other body systems, either in isolation or along
with typical dengue symptoms. Decreased sensitivity occurs in 0.5–6% of severe
cases, due to encephalitis or, indirectly, to compromised vital organs (e.g., hepatic
encephalopathy). Other neurological disorders similar to dengue, such as transverse
myelitis and Guillain-Barré syndrome, have been identified. Myocarditis and acute
liver failure are among the most rare complications.

7. Diagnosis

Signs and symptoms of dengue fever are similar to some other illnesses, such as
typhoid fever or malaria, which can sometimes hinder the likelihood of a timely and
correct diagnosis. It may be diagnosed by the patient’s signs and symptoms, patient’s
medical history, and testing blood samples (preliminary by platelet count, followed
by ELISA, HI assay, and RT-PCR).
The early and precise diagnosis of dengue infection in the laboratory is of para-
mount importance for disease control. It was estimated that the number of cases of
dengue misdiagnosed could reach a record of 50% of all cases, mainly due to a wide
disparity in dengue signs and symptoms that conflict with symptoms of other viral
infections, particularly for people living in or traveling to endemic areas of tropi-
cal infectious diseases. Until the antiviral vaccine is available, early and accurate
diagnosis relies heavily on the prevention of serious cases and the reduction of the
disease’s economic burden. To date, two screening methods have been employed for
early diagnosis of the disease. The first is a direct approach for the acute dengue dis-
ease phase which is focused on an antigen detection of genomic RNA from viremic
patient’s blood samples. The second is an indirect approach that relies on serological
tests to detect dengue-related immunoglobulins by Mac-ELISA for the capture of
real IgM or indirect ELISA for the capture of antiDEN IgGs.

7
Dengue Fever

Dengue diagnosis is usually performed clinically on the basis of recorded symp-

toms and physical examination, especially in endemic areas. However, early dengue
fever can be difficult to differentiate from other viral infections. Tourniquet testing,
which is particularly useful in environments where laboratory tests are not available,
includes applying a blood pressure cuff, inflating it to the midpoint between diastolic
and systolic pressure for 5 minutes, and then counting any petechial hemorrhages
that occur. The higher number of petechiae makes dengue diagnosis more likely; the
lower limit for diagnosis is variably specified as 10–20 petechiae per 2.5 cm2 [54].

8. Treatment

There are no particular antiviral medicines for dengue, but it is necessary to

maintain a proper fluid balance [55]. Treatment is dependent on the severity of
the symptoms. Those who can drink and pass urine have no warning signs can be
treated with daily follow-up and oral rehydration therapy at home. Those who have
serious health problems, who have warning signs, or who are unable to handle daily
follow-up should be admitted to the hospital for treatment. For areas with access
to an intensive care unit, treatment should be given for those with extreme dengue
fever. Intravenous hydration usually takes 1 or 2 days, if necessary. Fluid adminis-
tration dose is titrated to 0.5–1 mL/kg per hour of urinary output, stabilizing vital
signs, and normalizing hematocrit. The volume of fluid that is provided should be
the smallest to achieve such markers. Bearing in mind the risk of infection, invasive
medical procedures such as nasogastric intubation, intramuscular injections, and
arterial punctures should be avoided. Paracetamol (acetaminophen) is used for
fever and nausea, and it is important to avoid nonsteroidal anti-inflammatory drugs
such as ibuprofen and acetylsalicylic acid as they may increase the risk of bleeding.
For patients with compromised vital signs faced with declining hematocrit, blood
transfusion should begin early, rather than waiting for the concentration of hemo-
globin to decline to some predetermined “cause of transfusion” level. It is advised
to deliver red blood cells or whole blood; platelets and fresh, frozen plasma are not
typically recommended. Intravenous fluids are removed during the recovery phase
to avoid fluid overload. When fluid overload occurs and vital signs are stable, stop-
ping the administration of fluid can be all that is required to remove excess fluid. If
the individual is outside the critical phase, a diuretic loop, such as furosemide, may
be used to remove excess fluid from circulation.

9. Prevention

In December 2015, after decades of research and clinical progress, the first
dengue vaccine (CYD-TDV or Dengvaxia®, by Sanofi Pasteur) was authorized
[56]. Now regulatory authorities have approved it in ~20 countries.
CYD-TDV was found to be effective and safe in clinical trials in people who had
past infections with the dengue virus (seropositive individuals). It does, however,
bring an increased risk of severe dengue in those who undergo their first normal den-
gue infection after vaccination (those who were seronegative at vaccination time). It
was confirmed in November 2017 by the results of an additional retrospective study
analysis which determines the serostatus at the time of vaccination.
Pre-vaccination screening is the recommended strategy for countries which con-
sider vaccination as part of their dengue control program. With this approach only
individuals under evidence of past dengue infection would be vaccinated (based on
an antibody test or confirmed dengue infection in the past by a verified laboratory).

8
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

Decisions on implementing a pre-vaccination screening strategy would require care-

ful country-level evaluation, including consideration of the sensitivity and specificity
of the available tests and local priorities, dengue epidemiology, country-specific
hospitalization levels, and availability of both CYD-TDV and screening tests [57].
But prevention depends on the monitoring and safety of the bite of the mosquito
that transmits it. The primary tool used to monitor Aedes aegypti is by destroying its
habitats, which include standing water in urban areas (e.g., abandoned tires, ponds,
irrigation ditches, and open barrels). If habitat destruction is not possible, the applica-
tion of insecticides or biological control agents to standing water is another option.
Reducing open water collection is the preferred and simplest method of control.
Generalized spraying is often done with organophosphate or pyrethroid insecticides
but is not considered successful. People can avoid mosquito bites by wearing clothes
that completely cover the skin, wearing a repellent scarf, or staying in air-conditioned,
screened, or nested areas. However, these approaches do not seem to be sufficiently
effective, as the frequency of outbreaks in certain areas appears to be increasing, prob-
ably because urbanization is increasing the habitat of Aedes mosquitoes; however, the
range of diseases appears to be expanding, possibly due to climate change.

10. Conclusion

Dengue fever is a terrible disease and a growing public health problem. A rapid
increase in unplanned urbanization leads to more mosquito breeding sites, hence
a greater number of people are exposed to Aedes Aegypti mosquitoes bite. These
include semi-urban and slum areas where household water storage is normal and
where solid waste disposal facilities are inadequate. The urgent need for a vaccine
to minimize morbidity and mortality due to this disease has been recognized in a
cost-effective manner in recent years.

Conflict of interest

The authors have none to declare.

Author details

Ramalingam Kothai* and Balasubramanian Arul

Department of Pharmacology, Vinayaka Mission’s College of Pharmacy, Vinayaka
Mission’s Research Foundation (Deemed to be University), Salem, Tamil Nadu,
India

*Address all correspondence to: kothaiarul@yahoo.co.in

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.

9
Dengue Fever

References

[1] Cunha JP. Dengue fever [Internet]. [9] Tan FL-S, Loh DLSK,
MedicineNet. 2017. Available from: Prabhakaran K, Tambyah PA, Yap
https://www.medicinenet.com/dengue_ H-K. Dengue haemorrhagic fever after
fever/article.htm [Accessed: 02 January living donor renal transplantation.
2020] Nephrology, Dialysis, Transplantation.
2005;20(2):447-448. DOI: 10.1097/
[2] Gould EA, Solomon T. Pathogenic OGX.0b013e3181cb8fbc
flaviviruses. The Lancet (London,
England). 2008;371(9611):500-509. [10] Chen LH, Wilson ME. Nosocomial
DOI: 10.1016/S0140-6736(08)60238-X dengue by mucocutaneous transmission.
In: Emerging Infectious Diseases.
[3] Rodenhuis-Zybert IA, Wilschut J, 2005;11(5):775. DOI: 10.3201/eid1105.
Smit JM. Dengue virus life cycle: Viral 040934
and host factors modulating infectivity.
Cellular and Molecular Life Sciences. [11] Waggoner JJ, Gresh L, Vargas MJ,
2010;67(16):2773-2786. DOI: 10.1007/ Ballesteros G, Tellez Y, Soda KJ, et al.
s00018-010-0357-z Viremia and clinical presentation in
Nicaraguan patients infected with Zika
[4] Guzman MG, Halstead SB, virus, chikungunya virus, and dengue
Artsob H, Buchy P, Farrar J, Gubler DJ, virus. Clinical Infectious Diseases.
et al. Dengue: A continuing global 2016;63(12):1584-1590. DOI: 10.1093/
threat. Nature Reviews. Microbiology. cid/ciw589
2010;8(12 Suppl):S7-S16. DOI: 10.1038/
nrmicro2460
[12] Bhatt S, Gething PW, Brady OJ,
Messina JP, Farlow AW, Moyes CL, et al.
[5] WHO. Epidemiology, burden of
The global distribution and burden of
disease and transmission. In: Dengue:
dengue. Nature. 2013;496(7446):504-
Guidelines for Diagnosis, Treatment,
507. DOI: 10.1093/cid/ciw589
Prevention and Control. Geneva: World
Health Organization; 2009. pp. 3-25
[13] Anderson R, King AD, Innis BL.
[6] Pozzetto B, Memmi M, Garraud O. Correlation of E protein binding with
Is transfusion-transmitted dengue cell susceptibility to dengue 4 virus
fever a potential public health threat? infection. The Journal of General
World Journal of Virology [Internet]. Virology. 1992;73(Pt 8):2155-2159. DOI:
2015;4(2):113-123. DOI: 10.5501/wjv. 10.1099/0022-1317-73-8-2155
v4.i2.113
[14] Scott RM, Nisalak A, Cheamudon U,
[7] Pouliot SH, Xiong X, Harville E, Seridhoranakul S, Nimmannitya S.
Paz-Soldan V, Tomashek KM, Breart G, Isolation of dengue viruses from
et al. Maternal dengue and pregnancy peripheral blood leukocytes of patients
outcomes: A systematic review. with hemorrhagic fever. The Journal of
Obstetrical & Gynecological Survey. Infectious Diseases. 1980;141(1):1-6.
2010;65(2):107-118. DOI: 10.1097/ DOI: 10.1093/infdis/141.1.1
OGX.0b013e3181cb8fbc
[15] Kurane I, Ennis FA. Production
[8] Teo D, Ng LC, Lam S. Is dengue a of interferon alpha by dengue virus-
threat to the blood supply? Transfusion infected human monocytes. The Journal
Medicine [Internet]. 2009;19(2):66-77. of General Virology. 1988;69(Pt 2):445-
DOI: 10.1097/OGX.0b013e3181cb8fbc 449. DOI: 10.1099/0022-1317-69-2-445

10
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

[16] Kuno G, Chang GJ, Tsuchiya KR, [24] Leitmeyer KC, Vaughn DW,
Karabatsos N, Cropp CB. Phylogeny of Watts DM, Salas R, Villalobos I, de
the genus Flavivirus. Journal of Virology Chacon, et al. Dengue virus structural
[Internet]. 1998;72(1):73-83. DOI: differences that correlate with
10.1099/0022-1317-69-2-445 pathogenesis. Journal of Virology.
1999;73(6):4738-4747
[17] Surasombatpattana P, Hamel R,
Patramool S, Luplertlop N, Thomas F, [25] Lanciotti RS, Lewis JG, Gubler DJ,
Despres P, et al. Dengue virus replication Trent DW. Molecular evolution
in infected human keratinocytes leads and epidemiology of dengue-3
to activation of antiviral innate immune viruses. The Journal of General
responses. Infection, Genetics and Virology. 1994;75(Pt 1):65-75. DOI:
Evolution. 2011;11(7):1664-1673. DOI: 10.1099/0022-1317-75-1-65
10.1016/j.meegid.2011.06.009
[26] Bhattacharya MK, Maitra S,
[18] Tomashek KM. Dengue fever. Ganguly A, Bhattacharya A, Sinha A.
In: CDC Health Information for Dengue: A growing menace—A snapshot
International Travel 2012: The Yellow of recent facts, figures & remedies.
Book. USA: Oxford University Press; International Journal of Biomedical
2011 Science [Internet]. 2013;9(2):61-67

[19] Wilder-Smith A, Chen LH, [27] Messer WB, Gubler DJ, Harris E,
Massad E, Wilson ME. Threat of Sivananthan K, de Silva AM. Emergence
dengue to blood safety in dengue- and global spread of a dengue serotype
endemic countries. Emerging Infectious 3, subtype III virus. Emerging Infectious
Diseases. 2009;15(1):8-11. DOI: 10.3201/ Diseases. 2003;9(7):800-809. DOI:
eid1501.071097 10.3201/eid0907.030038

[20] Stramer SL, Hollinger FB, Katz LM, [28] Halstead SB. Etiologies of the
Kleinman S, Metzel PS, Gregory KR, experimental dengues of Siler and
et al. Emerging infectious disease Simmons. The American Journal
agents and their potential threat of Tropical Medicine and Hygiene.
to transfusion safety. Transfusion. 1974;23(5):974-982. DOI: 10.4269/
2009;49(Suppl 2):1S-29S. DOI: ajtmh.1974.23.974
10.1111/j.1537-2995.2009.02279.x
[29] Halstead SB, Nimmannitya S,
[21] Wiwanitkit V. Unusual mode of Cohen SN. Observations related to
transmission of dengue. Journal of pathogenesis of dengue hemorrhagic
Infection in Developing Countries. fever. IV. Relation of disease severity to
2009;4(1):51-54. DOI: 10.3855/jidc.145 antibody response and virus recovered.
The Yale Journal of Biology and
[22] Chen LH, Wilson ME. Dengue and Medicine. 1970;42(5):311-328
chikungunya infections in travelers.
Current Opinion in Infectious Diseases. [30] Sangkawibha N, Rojanasuphot S,
2010;23(5):438-444. DOI: 10.1097/ Ahandrik S, Viriyapongse S,
QCO.0b013e32833c1d16 Jatanasen S, Salitul V, et al. Risk
factors in dengue shock syndrome: A
[23] Simmons CP, Farrar JJ, van prospective epidemiologic study in
Vinh CN, Wills B. Dengue. The New Rayong, Thailand. I. The 1980 outbreak.
England Journal of Medicine [Internet]. American Journal of Epidemiology.
2012;366(15):1423-1432. DOI: 10.1056/ 1984;120(5):653-669. DOI: 10.1093/
NEJMra1110265 oxfordjournals.aje.a113932

11
Dengue Fever

[31] Guzman MG, Kouri G, Valdes L, [38] Vaughn DW, Green S, Kalayanarooj S,
Bravo J, Alvarez M, Vazques S, Innis BL, Nimmannitya S, Suntayakorn S,
et al. Epidemiologic studies on et al. Dengue viremia titer, antibody
dengue in Santiago de Cuba, 1997. response pattern, and virus serotype
American Journal of Epidemiology. correlate with disease severity. The
2000;152(9):793-799; discussion 804. Journal of Infectious Diseases. 2000;
DOI: 10.1093/aje/152.9.793 181(1):2-9. DOI: 10.1086/315215

[32] Halstead SB. Antibody, [39] Hammond SN, Balmaseda A,

macrophages, dengue virus infection, Perez L, Tellez Y, Saborio SI,
shock, and hemorrhage: A pathogenetic Mercado JC, et al. Differences in dengue
cascade. Reviews of Infectious Diseases. severity in infants, children, and
1989;11(Suppl 4):S830-S839. DOI: adults in a 3-year hospital-based study
10.1093/clinids/11.supplement_4.s830 in Nicaragua. The American Journal
of Tropical Medicine and Hygiene.
[33] Halstead SB, Heinz FX, 2005;73(6):1063-1070
Barrett ADT, Roehrig JT. Dengue
virus: molecular basis of cell entry and [40] Chan M, Johansson MA. The
pathogenesis, 25-27 June 2003, Vienna, incubation periods of Dengue viruses.
Austria. Vaccine. 2005;23:849-856. DOI: PLoS One [Internet]. 2012;7(11):e50972.
10.1016/j.vaccine.2004.03.069 DOI: 10.1371/journal.pone.0050972

[41] Guha-Sapir D, Schimmer B. Dengue

[34] Kouri GP, Guzman MG, Bravo JR,
fever: New paradigms for a changing
Triana C. Dengue haemorrhagic fever/
epidemiology. Emerging Themes in
dengue shock syndrome: Lessons from
Epidemiology [Internet]. 2005;2(1):1.
the Cuban epidemic, 1981. Bulletin
DOI: 10.1186/1742-7622-2-1
of the World Health Organization.
1989;67(4):375-380
[42] Khan NA, Azhar EI, El-Fiky S,
Madani HH, Abuljadial MA, Ashshi AM,
[35] de la C Sierra B, Kouri G,
et al. Clinical profile and outcome
Guzman MG. Race: A risk factor for
of hospitalized patients during first
dengue hemorrhagic fever. Archives of
outbreak of dengue in Makkah, Saudi
Virology. 2007;152(3):533-542. DOI:
Arabia. Acta Tropica. 2008;105(1):39-44.
10.1007/s00705-006-0869-x
DOI: 10.1016/j.actatropica.2007.09.005
[36] Avirutnan P, Malasit P, Seliger B, [43] Ooi E-E, Goh K-T, Gubler DJ.
Bhakdi S, Husmann M. Dengue virus Dengue prevention and 35 years of
infection of human endothelial cells vector control in Singapore. Emerging
leads to chemokine production, Infectious Diseases. 2006;12(6):887-893.
complement activation, and DOI: 10.3201/10.3201/eid1206.051210
apoptosis. Journal of Immunology.
1998;161(11):6338-6346 [44] Low JGH, Ooi E-E, Tolfvenstam T,
Leo Y-S, Hibberd ML, Ng L-C, et al.
[37] Cardier JE, Marino E, Romano E, Early dengue infection and outcome
Taylor P, Liprandi F, Bosch N, et al. study (EDEN)—Study design and
Proinflammatory factors present in preliminary findings. Annals of the
sera from patients with acute dengue Academy of Medicine, Singapore.
infection induce activation and 2006;35(11):783-789
apoptosis of human microvascular
endothelial cells: Possible role of [45] Wichmann O, Jelinek T. Dengue in
TNF-alpha in endothelial cell damage in travelers: A review. Journal of Travel
dengue. Cytokine. 2005;30(6):359-365. Medicine. 2004;11(3):161-170. DOI:
DOI: 10.1016/j.cyto.2005.01.021 10.2310/7060.2004.18503

12
Dengue Fever: An Overview
DOI: http://dx.doi.org/10.5772/intechopen.92315

[46] Schexneider KI, Reedy EA. [55] Ramalingam K, Varghese CS, Elias C,
Thrombocytopenia in dengue Mathew GM, Balasubramanian A,
fever. Current Hematology Reports. Nadu T. A retrospective study on the
2005;4(2):145-148 effect of Vitamin C in the management
of dengue fever in three different
[47] Martina BEE, Koraka P, states of India. International Journal of
Osterhaus ADME. Dengue virus Research in Pharmaceutical Sciences.
pathogenesis: An integrated view. 2019;10(4):2670-2673. DOI: 10.26452/
Clinical Microbiology Reviews. ijrps.v10i4.1525
2009;22(4):564-581. DOI: 10.1128/
CMR.00035-09 [56] Vannice KS, Wilder-Smith A,
Barrett ADT, Carrijo K, Cavaleri M,
[48] Noisakran S, Chokephaibulkit K, de Silva A, et al. Clinical development
Songprakhon P, Onlamoon N, Hsiao and regulatory points for consideration
H-M, Villinger F, et al. A re-evaluation for second-generation live attenuated
of the mechanisms leading to dengue dengue vaccines. Vaccine [Internet].
hemorrhagic fever. Annals of the 2018;36(24):3411-3417. DOI: 10.1016/j.
New York Academy of Sciences. vaccine.2018.02.062
2009;1171(Suppl 1):E24-E35. DOI:
10.1111/j.1749-6632.2009.05050.x [57] WHO. Dengue vaccine: WHO
position paper, September 2018-
[49] Marques N, Gan VC, Leo Y-S.
Recommendations. Vaccine [Internet].
Dengue myocarditis in Singapore: Two 2019;37(35):4848-4849. DOI: 10.1016/j.
case reports. Infection. 2013;41(3):709- vaccine.2018.09.063
714. DOI: 10.1007/s15010-012-0392-9

[50] Misra UK, Kalita J, Syam UK,

Dhole TN. Neurological manifestations
of dengue virus infection. Journal
of the Neurological Sciences.
2006;244(1-2):117-122. DOI: 10.1016/j.
jns.2006.01.011

[51] Whitehorn J, Farrar J. Dengue.

British Medical Bulletin. 2010;95:
161-173. DOI: 10.1093/bmb/ldq019

[52] Reiter P. Yellow fever and

dengue: A threat to Europe? Euro
Surveillance: Bulletin Europeen Sur les
Maladies Transmissibles = European
Communicable Disease Bulletin.
2010;15(10):19509

[53] Varatharaj A. Encephalitis in the

clinical spectrum of dengue infection.
Neurology India. 2010;58(4):585-591.
DOI: 10.4103/0028-3886.68655

[54] Ranjit S, Kissoon N. Dengue

hemorrhagic fever and shock
syndromes. Pediatric Critical Care
Medicine. 2011;12(1):90-100. DOI:
10.1097/PCC.0b013e3181e911a7

13